

July 23-25, 2019 | Boston, MA, USA

www.npd-summit.com

**Book Now & Save
Up To \$700**



2nd Annual

NPD

Neuropsychiatric Drug Development

Advancing the Development of Clinically Transformative Neuropsychiatric Drugs

20 Expert Speakers, Including:



Al Robichaud
Chief Scientific
Officer
Sage Therapeutics



Eric Schaeffer
Senior Director,
Neuroscience
Innovation
**Johnson &
Johnson**



Andreas Meier
Senior Medical
Director
Biogen



Jason Uslaner
Executive Director,
Neuroscience
Merck

**Innovation
Partners:**



*Cognitive
Research
Corporation*

**Panel
Partner:**



The Neuropsychiatric Drug Development Summit (NPD)

Overcome Your Drug Development Challenges to Advance Towards Clinically Transformative Neuropsychiatric Drugs

Built with industry thought leaders at **Lundbeck**, **Sage Therapeutics** and **Johnson & Johnson**, the **2nd Annual Neuropsychiatric Drug Development (NPD) Summit** will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs and reveal the latest scientific advances in the field.

Dedicated to overcoming challenges in neuropsychiatric drug development, this comprehensive discussion and networking forum will enable you to:

- Review the current clinical landscape to **predict potential success and identify future opportunities**
- Develop your biological understanding of neuropsychiatric disorders and the genetic influences involved in order to **improve your target and approach selection**
- Discuss and debate the field's hottest topics including the potential for **digital therapeutics and precision medicine**

Don't miss the opportunity to join 80+ of your peers to learn, share and discuss your future strategies to advance towards successful neuropsychiatric therapeutics.

Hear what last year's attendees have to say:

■ It was a well-organized conference ■

Gopi Shanker, Director, **Novartis**

■ Very good conference ■

Christopher Missling, Chief Executive Officer & President, **Anavex Life Sciences**

■ Very well organized conference with exceptional speakers ■

Linda Hedley, Business Development Consultant, **SRI International**


■ It was a well-organized and terrific conference with plenty of meaningful inputs ■

Tatsuro Nakagawa, Manager, **Akros Pharma Inc.**

Join us at NPD to:



Familiarize yourself with the translational strategies available to determine what we can expect from neuropsychiatric preclinical models to **better predict clinical efficacy**



Discover the latest advances in neuropsychiatric drug development technologies such as digital biomarkers to **monitor disease progression**



Share your neuropsychiatric research at the Poster Session with your peers to **receive constructive feedback and spark conversation with potential collaborators**



Review symptomatic focused drug development to **identify the benefits and impact on future regulation**



Evaluate the potential for different neuropsychiatric targets by **improving our understanding of neuropsychiatric biology**

Your Expert Speakers



Al Robichaud
Chief Scientific Officer
Sage Therapeutics



Andreas Meier
Senior Medical
Director,
Ophthalmology, Pain
& New Indications
Biogen



Alan Schatzberg
Professor, Psychiatry &
Behavioral Sciences
Stanford University



Bruce Kimmel
Chief Executive Officer
Vidrio Technologies



Christopher Missling
Chief Executive Officer
Anavex Life Sciences



Daniel Hoepfner
Associate Director
Astellas



Elise Robinson
Assistant Professor
Harvard University



Eric Schaeffer
Senior Director,
Neuroscience
Innovation
Johnson & Johnson



Gary Kay
President
**Cognitive Research
Corporation**



George Papakostas
Scientific Director
**Massachusetts
General Hospital
Clinical Trials
Network & Institute**



Gopi Shanker
Director, Head of
Psychiatry
Novartis



James Cassella
Chief Development
Officer
**Concert
Pharmaceuticals**



Jason Uslaner
Executive Director,
Neuroscience
Merck



Joris Van Dam
Executive Director,
Head of Digital
Therapeutics
Novartis



Kevin Sanders
Global Development
Lead Autism
Roche



Laura Corradini
Deputy Global Head
Business Development
& Licensing, CNS
Boehringer Ingelheim



Nick Brandon
Senior Vice President
Jnana Therapeutics



Seth Hopkins
Executive Director,
Translational Medicine
Sunovion



Shil Patel
Vice President
Codiak BioSciences



Stevin Zorn
President & Chief
Executive Officer
**MindImmune
Therapeutics Inc**



Sylvain Celanire
Chief Executive Officer
**PRAGMA
Therapeutics**

Pre-Conference Workshops

Tuesday, July 23

Workshop A

8:00am – 11:00am

Understanding the Role of Genetics in Neuropsychiatric Disorders

Recent technological advances have provided us with the ability to understand the genetic influences on neurodevelopmental variation, as well as the ability to study differences within and between neuropsychiatric disorders. The genetic risk factors for severe neuropsychiatric disorders will be introduced in this workshop.

By attending this workshop, you will:

- Be introduced to types of genetic variation
- Learn about our current understanding of the role of genetics in different neuropsychiatric disorders
- Discuss how this may affect our ability to treat these disorders in the future

Workshop Leader



Elise Robinson
Assistant Professor
Harvard University

Workshop B

11:30am – 2:30pm

Reviewing the Potential for Precision Medicine in Neurological Diseases

With the advances in next-generation sequencing, the possibilities for genetic stratification of neuropsychiatric disease have great potential with both individual treatment optimization and clinical trial design.

Attend this workshop to:

- Learn about the technology advances changing the precision medicine landscape
- Understand which neuropsychiatric diseases would be most compatible for precision medicine treatment
- Discuss and debate the pros and cons of the precision medicine approach
- Review the available data for case studies of precision medicine

Workshop Leader



Christopher Missling
Chief Executive
Officer
**Anavex Life
Sciences**

Workshop C

3:00pm – 6:00pm

Mitigating & Removing Risk in Clinical Trials

The frustrations and challenges in the neuropsychiatry space over the years have been evident. With large studies failing in phase II/III, drug development costs and timelines have skyrocketed, prompting many Industry leaders in the field to scrap their Psychiatry or CNS divisions. Innovators in Academia and Industry have stepped up efforts to mitigate risk and, hence, design and conduct to more effective and productive trials.

Attendees will discuss in detail:

- Using clinically validated paradigms that don't rely on pre-clinical models to mitigate risk in clinical trials
- Review of successful study design elements
- Review common pitfalls to avoid when designing and executing trials

Workshop Leader



George Papakostas
Scientific Director
**Massachusetts
General Hospital
Clinical Trials
Network & Institute**

Conference Day One

Wednesday, July 24

8.00 Chair's Opening Remarks

Reviewing the Neuropsychiatric Clinical Landscape: Where Are We Now?

Al Robichaud
Chief Scientific
Officer
Sage Therapeutics

8.15 The Progress in Rapid-Acting Antidepressants

- Depression remains a significant area of unmet need
- The discovery work done at Sage is demonstrating that small disruptions to GABA signaling can have far-reaching effects on mood and behavior
- As we continue to study the interplay of signaling and the response in complex neural networks, following GABA's path is illuminating new opportunities to treat CNS disorders long seen as intractable

Gopi Shanker
Director, Head of
Psychiatry
Novartis

8.45 Moving from Treatment to Cure in Neuropsychiatric Disorders: What Will It Take?

- Current efforts to address unmet need in neuropsychiatric disorders are focused on symptomatic improvement
- Recent advances in the genetics of neuropsychiatric disorders as well as longitudinal studies in patients have led to a renewed focus on development of effective therapies in this area
- This talk will raise the exciting idea of moving from treatment to cure and how the recent advances in the genetics and biology of neuropsychiatric disorders might outline a path



9.15 Speed Networking

This session is the ideal opportunity to meet face-to-face with the key thought leaders working in the neuropsychiatric drug development field. Specifically designed to connect you with new contacts from the most active companies in the field, the renowned Speed Networking session will be one of the most valuable hours you will spend at NPD

10.00 Morning Refreshments

Utilizing Translational Strategies to Advance the Neuropsychiatric Pipeline

Jason Uslaner
Executive Director,
Neuroscience
Merck

11.00 Reducing the Translational Gap in Neuropsychiatry

- What is the translational gap and why is it important?
- How might the translational gap be addressed?
- Lessons learned from discovery efforts at Merck

Seth Hopkins
Executive Director,
Translational
Medicine
Sunovion

11.30 A Novel Approach Using PANSS to Characterize Specificity & Effectiveness of New Mechanisms Among the Symptom Dimensions of Schizophrenia

- Understanding the specificity of symptom change in schizophrenia can facilitate the evaluation of antipsychotics' efficacy profiles across symptom domains
- Existing clinical trial databases identified a transform of PANSS using an uncorrelated PANSS score matrix (UPSM) to reduce pseudospecificity among symptom domains in antipsychotic-treated patients with schizophrenia
- We propose novel constructs for more-accurate depictions of drug efficacy, and to apply these to the clinical development and differentiation of novel therapeutics

12.00 Lunch & Networking

Developing Neuropsychiatric Biomarkers to Aid Future Preclinical & Clinical Research

Kevin Sanders Global Development Lead Autism Roche	1.00 How Are Digital Biomarkers Transforming Neuropsychiatric Drug Development? • Discussing the need for digital biomarkers in neuropsychiatry • Exploring the evolving technology • Discuss the use case for digital biomarkers in autism
Shil Patel Vice President Codiak BioSciences	1.30 An Overview of Developing PET/SPECT Ligands for CNS Drug Research & Development • Application of nuclear imaging techniques in CNS drug R&D • Recent developments and learnings
	2.00 Afternoon Refreshments & Networking

Assessing Methods for Improving Pharmaceutical Success

James Cassella Chief Development Officer Concert Pharmaceuticals	3.00 Adjunctive Therapies in the Treatment of Primary Symptoms of Schizophrenia • Atypical antipsychotics represent the main drug class in treating schizophrenia • Adjunctive medications can enhance the benefits of atypical antipsychotic drug monotherapy • Current approaches to adjunctive therapy for schizophrenia will be reviewed
Joris Van Dam Executive Director, Head of Digital Therapeutics Novartis Kevin Sanders Global Development Lead Autism Roche	3.30 Panel Discussion: The Future of Digital Therapeutics – Working Alongside Pharmaceuticals to Transform Therapeutic Success • Reviewing the potential for digital therapeutics in different neuropsychiatric disorders • Assessing research success in this field this far • Accounting for the challenges and risks involved with digital therapeutics
	4.15 Chair's Closing Remarks
	4.30 Scientific Poster Session After the formal presentations have finished, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. You will have the opportunity to present and review presentations displaying new data from neuropsychiatric disease research, such as novel therapeutic targets and advances in clinical development.

 Very well organized conference with exceptional speakers.
 Well represented across Pharma / Biotech / Academics/
 Service providers 

Linda Hedley, Business Development Consultant, **SRI International**

Conference Day Two

Thursday, July 25

8.15 Chair's Opening Remarks

Transforming the Approaches for Treating Neuropsychiatric Disease

Andreas Meier
Senior Medical
Director,
Ophthalmology, Pain
& New Indications
Biogen

8.30 Accounting for the Cognitive Symptoms of Schizophrenia to Improve Patient Quality of Care

- Why cognition is a symptom to be acknowledged in neuropsychiatric drug development
- Discussing the relevance and consequences of cognitive symptoms in schizophrenia
- Considerations for the clinical assessment of cognition and its relationship to functional improvement

Laura Corradini
Deputy Global
Head Business
Development &
Licensing, CNS
**Boehringer
Ingelheim**

9.00 Symptomatic-focused Treatment – Transforming the Drug Development Approach to Neuropsychiatry

- Unmet medical needs in neuropsychiatry
- Novel treatments: the challenges ahead
- Partnering: a way to bring innovative treatments to patients

9.30 Morning Refreshments & Networking

Accelerating the Development of Efficacious Neuropsychiatric Therapeutics

Bruce Kimmel
Chief Executive
Officer
Vidrio Technologies

10.45 Measuring Brain Activity in Alive Awake Animals

- 2-Photon microscope allows neuronal activity to be imaged in real time and correlated with behavior
- New electrophysiology approaches are allowing larger regions of the brain to be surveyed with extra-cellular recordings

Eric Schaeffer
Senior Director,
Neuroscience
Innovation
Johnson & Johnson

11.00 What is Needed to Develop More Efficacious Treatments for Neuropsychiatric Disorders?

- Heterogeneity of psychiatric disorders
- Learning from clinical experience
- Human disease genetics

11.30 Lunch & Networking

Evaluating the Potential for Different Neuropsychiatric Targets

Stevin Zorn
President & Chief
Executive Officer
**MindImmune
Therapeutics Inc**

12.30 KMO Inhibitors for Depression Co-Morbid with Chronic Inflammatory Disease

- Depression resistant to SSRIs is highly co-morbid with both neuroinflammatory and systemic inflammatory disease
- Inhibition of KMO prevents formation of toxic kynurenine metabolites that are the immune effectors of inflammation-associated depression
- It is essential to block KMO in microglia in the brain to realize the efficacy of KMO inhibitors

Sylvain Celanire Chief Executive Officer PRAGMA Therapeutics	1.00 MGlur7 Receptor Blockade: An Evident Therapeutic Approach for Neuropsychiatric Disorders • The glutamatergic approach beyond NMDA receptor modulation • Association of GRM7 gene with various human CNS pathologies • mGlu7 as a unique Class C GPCR target to address neuropsychiatric disorders • Proof-of-concept of clinical candidate in PTSD and schizophrenia
Alan Schatzberg Professor, Psychiatry & Behavioral Sciences Stanford University	1.30 Mechanism of Action of Ketamine: Implications for Clinical Practice • Interpreting ketamine's opioid effects in antidepressant response • Exploring the risk /benefit ratio of longer term use of ketamine • What should we recommend to clinicians on the longer term use of ketamine?
	2.00 Afternoon Networking & Refreshments
Evaluating the Genetic Progress in Neuropsychiatric Research	
Daniel Hoepfner Associate Director Astellas	3.00 From Human Genetics to Actionable Targets • What have we learned from public data? • Power of cell-type selectivity in GWAS
Christopher Missling Chief Executive Officer Anavex Life Sciences Nick Brandon Senior Vice President Jnana Therapeutics	3.30 Panel Discussion: The Precision Medicine Approach to Neuropsychiatry – For or Against? • How effective could precision medicine be for certain neuropsychiatric disorders? • What are the success stories to support precision medicine? • Where are doubts coming from?
	4.00 Chair's Closing Remarks

■ I liked the conference and the chance to interact with many of the sponsors ■

David Walling, Chief Executive Officer, **CNS Network, LLC**

Partnership Opportunities

Why Partner

Partnering with **NPD** is your opportunity to demonstrate your expertise in front of the leading minds of neuropsychiatric drug development.

With 80+ decision makers of pharmaceutical and biotech companies converging at **NPD**, this forum will be a unique opportunity for you to demonstrate how your company can help drug developers overcome their barriers preventing the development of next generation neuropsychiatric drugs.

Experts from **Sage Therapeutics, Lundbeck, Johnson & Johnson, Biogen** and other leading companies in the space are actively seeking partners to help them:

-  Identify novel biomarkers and technologies that can be used to advance both preclinical and clinical research to improve quantification and trial efficiency
-  Design clinical trials in order to mitigate risk and improve clinical success

We will work with you to build a bespoke partnership to ensure that you meet your 2019 business objectives.

Get in touch today to learn more about how we can support you: sponsor@hansonwade.com



Innovation Partner

Vidrio Technologies was spun out of the Howard Hughes Medical Institute in 2013 to commercialize two-photon laser-scanning microscopy (TPLSM) software, hardware, and imaging services. The company's primary products are the software package ScanImage® and control electronics that interfaces with microscopes. Vidrio's software optimizes imaging for a new 5mm field of view TPLSM that allows half of a functioning mouse brain to be imaged with cellular resolution. Large-scale electrophysiology analysis software is also a Vidrio product.

www.vidriotechnologies.com



Innovation Partner

Cognitive Research Corporation (CRC) is a mid-size full-service CRO specializing in CNS and early phase product development. CRC's seasoned team of professionals provide services that are comprehensive, flexible, quality-driven, and cost-effective. CRC has relationships with high quality sites as well as thought leaders in complex phase I-III trial designs and CNS specialties. In addition to CRO services, CRC has developed proprietary technologies, including the CRC Driving Simulator (CRCDS), applicable in a broad range of studies.

www.alliancesites.com



Panel Partner

Rho, a contract research organization (CRO) located in Chapel Hill, NC, provides a full range of services across the entire drug development process. For more than 30 years, Rho has been a trusted partner to leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, innovative technologies, and therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.

www.rhoworld.com

Get involved



Okeefe Ogholo

Business Development Manager

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

Ready to Register?

3 easy ways to book



www.npd-summit.com



Tel: +1 617 455 4188



Email: register@hansonwade.com

- 1 Network with neuropsychiatric thought leaders to improve your connections with the field for future collaborations
- 2 Widen your knowledge of the scientific progress in the neuropsychiatric field and keep up to date with the latest technology advances
- 3 Discover the strategies developed or used by your peers to help overcome your translational challenges

Team Discounts

20% discount: 5 or more delegates


15% discount: 4 delegates

10% discount: 3 delegates

Secure your place

Package Details	Register & Pay before Friday, Friday, May 10	Standard Pricing
Gold: Conference & 3 workshops	\$4196 (save \$700)	\$4396 (save \$500)
Silver: Conference & 2 workshops	\$3697 (save \$500)	\$3897 (save \$300)
Bronze: Conference & 1 workshop	\$3198 (save \$300)	\$3398 (save \$100)
Conference only	\$2599 (save \$200)	\$2799
Workshops - Individual	\$699	

For academic rates, please contact register@hansonwade.com



Venue

Wyndham Boston Beacon Hill

5 Blossom Street, Boston, MA 02114

For further information or assistance, please visit

www.wyndhambeaconhill.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH